GSK’s fair value estimate has seen a modest increase, rising from $16.63 to $17.36 per share. The discount rate remains ...

GSK plc (NYSE:GSK) on Wednesday announced plans to invest $30 billion across the United States in research and development and supply chain infrastructure over the next five years. The update includes ...

GSK plc GSK has unveiled a $30 billion investment plan in research and development (R&D) and supply chain infrastructure in the United States, which will be executed over the next five years. GSK’s ...

Pharma giant GSK and venture capital-backed Elegen are partnering to leverage the DNA manufacturer's proprietary technology to help develop new vaccines and medicines. Under the deal, Elegen could net ...

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min Pennsylvania is providing GSK ...

India's GlaxoSmithKline Pharmaceuticals reported slightly higher second-quarter profit on Thursday, led by steady demand for ...

This cooperation aims to expedite access to advanced medicines and vaccines developed by GSK, particularly by bringing to ...

Revenue from operations stood at ₹974 crore, reflecting a temporary topline dip due to GST-related transitions, seasonal ...

GlaxoSmithKline ( ($GB:GSK) ) has provided an announcement. GSK plc has announced provisional dividend dates for the year 2026, outlining key ...

South Korea’s Ministry of Food and Drug Safety issued a pair of administrative penalties to GSK for manufacturing and labeling problems on certain asthma and acne treatments, Korea Biomedical Review ...

GSK’s entry into Oncology with the launch of specialised therapies Jemperli (Dostarlimab) and Zejula (Niraparib) was well-received by healthcare professionals. Shares of GlaxoSmithKline ...